For example, studies have shown that the expression level is upregulated in CD19+ B cells from CLL, whereas its level was observed to be downregulated in CML and ALL (He Y. et al., 2014; Mraz et al., 2014). This evidence concerns the gene CD19 and chronic myelogenous leukemia, BCR-ABL1 positive.